-
Mashup Score: 4Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy - 5 day(s) ago
China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 3
When given alone or with tumor infiltrating lymphocyte therapy, TILT-123 given intravenously or intratumorally is safe and feasible for patients with advanced metastatic melanoma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy - 10 day(s) ago
China’s NMPA has approved tunlametinib for the treatment of patients with NRAS-mutated advanced melanoma after prior anti–PD-1/PD-L1 therapy.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Dr Olson on the FDA Approval of Lifileucel for Advanced Melanoma - 14 day(s) ago
Daniel Olson, MD, discusses the FDA approval of lifileucel for patients with advanced melanoma whose disease has been previously treated.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Experience Shapes Use of Dual Immunotherapy in Advanced Melanoma - 27 day(s) ago
During a Targeted Oncology™ Case-Based Roundtable™ event, Michael B. Atkins, MD, discussed what patient factors and other considerations affect the choice of immunotherapy for patients with advanced BRAF-negative melanoma. This is the first of 2 articles based on this event.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Early FDG PET/CT Scanning May Predict Treatment Response in Melanoma - 1 month(s) ago
Imaging after 1 week of treatment with pembrolizumab may help identify treatment responses in patients with metastatic melanoma.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Accelerated Approval Given to Lifileucel in Metastatic Melanoma - 1 month(s) ago
Patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody can now receive lifileucel after accelerated approval from the FDA.
Source: www.cancernetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Dr Kluger on the FDA Approval of Lifileucel in Advanced Melanoma - 1 month(s) ago
Harriet Kluger, MD, discusses the FDA approval of the tumor infiltrating lymphocyte therapy lifileucel for patients with advanced melanoma.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
In the treatment of unresectable or metastatic Merkel cell carcinoma, immune checkpoint inhibitors have activity and tolerability.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
Tunlametinib Wins Approval in China for NRAS+ Advanced Melanoma After PD-1/PD-L1 Therapy #melsm https://t.co/yXk7NNe8V3